NCT04844489View on ClinicalTrials.gov

Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People

NACompletedINTERVENTIONAL
Enrollment

377

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

November 24, 2022

Study Completion Date

December 31, 2022

Conditions
Autoimmune or Autoinflammatory DiseasesHIVMultiple SclerosisSolid Tumors or CancersSolid Organ Transplant
Interventions
OTHER

Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19

"Blood samples at:~* D0 (the day of the injection of the SARS-CoV-2 vaccine),~* during the 2nd injection as part of the national vaccination campaign (on D28)~* during the 3rd injection for patients for whom a third injection is recommended (according to the recommendations in force)~* then to M1, M6 and M12 of the last injection"

Trial Locations (1)

75013

Hospital Pitié-Salpêtrière - AP-HP, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER